Nautilus Biotechnology, Inc. (NAUT) Institutional Ownership

Ownership Summary

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) currently has 16 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• Institutional ownership in Nautilus Biotechnology edged down to 4.1% in December 2025, compared to 46.1% in September 2025.
• Quarterly data indicates a 22.67% shift in institutional share volume, and the annual owner count reflects a decrease of 82.22%.
• The latest 13F cycle for Nautilus Biotechnology reveals that of 16 total investors, 4 funds grew their exposure, whereas 3 reduced theirs and 9 made no changes.
• The aggregate institutional position in Nautilus Biotechnology now stands at 5.12Mn shares as of December 2025, after investors increased their holdings (up by 946.48K shares quarter on quarter which is down 58.75Mn shares year over year).
• As of December 31, 2025, VANGUARD GROUP INC held Nautilus Biotechnology's largest shareholding position with over 2.60Mn shares, representing 2.07% of total outstanding shares.
• Among the most significant buyers of Nautilus Biotechnology during December 2025 were SENTINEL TRUST CO LBA (750.00K), VANGUARD GROUP INC (166.39K), Caprock Group, LLC (27.00K), UBS Group AG (4.69K).
• Leading sellers of Nautilus Biotechnology stock in December 2025 included Palumbo Wealth Management LLC (984), Vanguard Capital Wealth Advisors (500), CWM, LLC (127).
• The top 10 institutional holders of Nautilus Biotechnology for the quarter ending December 2025 included VANGUARD GROUP INC (2.60Mn), Clarius Group, LLC (1.21Mn), SENTINEL TRUST CO LBA (750.00K), HILLMAN CO (200.00K), Crewe Advisors LLC (136.05K), Ashton Thomas Private Wealth, LLC (45.00K), Caprock Group, LLC (44.09K), Palumbo Wealth Management LLC (41.13K), Presidio Capital Management, LLC (34.66K), Badgley Phelps Wealth Managers, LLC (30.00K).